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Abstract
Background:  Melanoma is the most aggressive form of skin cancer, and the most rapidly
expanding cancer in terms of worldwide incidence. Chemotherapeutic approaches to treat
melanoma have been uniformly disappointing. A Brazilian complex homeopathic medication
(CHM), used as an immune modulator, has been recommended for patients with depressed
immune systems. Previous studies in mice have demonstrated that the CHM activates
macrophages, induces an increase in the number of leukocytes and improves the murine response
against Sarcoma-180.
Methods: Here we studied the interaction of mouse lymph node lymphocytes, co-cultured in vitro
with macrophages in the presence or absence of the CHM, with B16F10 melanoma cells.
Results: Lymphocytes co-cultured with macrophages in the presence of the CHM had greater
anti-melanoma activity, reducing melanoma cell density and increasing the number of lysed tumor
cells. There was also a higher proportion of activated (CD25+) lymphocytes with increased viability.
Overall, lymphocytes activated by treatment destroyed growing cancer cells more effectively than
control lymphocytes.
Conclusion: Co-culture of macrophages with lymphocytes in the presence of the CHM enhanced
the anti-cancer performance of lymphocytes against a very aggressive lineage of melanoma cells.
These results suggest that non-toxic therapies using CHMs are a promising alternative approach to
the treatment of melanomas. In addition, they are attractive combination-therapy candidates, which
may enhance the efficacy of conventional medicines by improving the immune response against
tumor cells.
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Background
Melanoma represents a significant worldwide public
health risk, and from the standpoint of incidence, consti-
tutes the fastest growing of all cancer types. Malign
melanoma is the most aggressive form of skin cancer, with
a mortality rate that has risen about 2% annually since
1960. Although early stage melanoma can be cured surgi-
cally, once melanoma metastasizes to major organs (stage
IV), it is virtually incurable. Patients with advanced
melanoma have a median survival time of less than one
year, and the estimated 5-year survival rate is less than
15% [1].
Melanoma has aggressive metastatic potential, particu-
larly to lymph nodes, lung and brain. Reports of metas-
tases to other organs, including bone, pancreas, adrenals
and small intestine, have also been described. There are
few chemotherapeutic agents available for treating meta-
static melanoma, and those that have been used have
achieved uniformly disappointing results. No single
chemotherapeutic agent currently offers a response rate
greater than 25%, and treatment is invariably accompa-
nied by significant side effects, including myelosuppres-
sion, nausea and emesis [1,2].
Immunotherapy remains the subject of intense investiga-
tion in both adjuvant and advanced disease settings, and
attempts are being made to target melanoma defense
mechanisms that blunt the effectiveness of host immune
responses. However, there are few laboratory reports on
homeopathic medicines in the medical literature; of those
that have been published, most are clinical reports that
have employed varied methodologies and yielded contro-
versial, and often questionable, results. Despite this pau-
city of basic research, a large number of people continue
to use such therapies. In Europe, homeopathy is the most
frequent complementary and alternative medical therapy
[3]. Here we describe the results of an experimental labo-
ratory validation of the potential of peritoneal macro-
phages, challenged with a complex homeopathic
medication (CHM), to stimulate the immune effective-
ness of mesenteric lymph node lymphocytes (Ly). This
new form of immunomodulatory therapy is based on
Hahnemann's ancient homeopathic techniques, which
use diluted substances that are vigorously shaken (suc-
cussed) during preparation.
Previous studies have demonstrated that CHM treatment
activates macrophages both in vivo and in vitro, inducing
several molecular modifications in macrophages. CHM
treatment has been shown to suppress previously elevated
levels of tumor necrosis factor-α (TNF-α), and increase the
activity of NADPH oxidase and expression of inducible
nitric oxide synthase (iNOS), resulting in increases in
reactive oxygen species (ROS) and nitric oxide (NO),
respectively [4,5]. In addition, a CHM has been shown to
stimulate the endosomal/lysosomal system and increase
the phagocytic activity of macrophages upon interaction
with Saccharomyces cerevisiae and Trypanosoma cruzi epi-
mastigotes [6]. CHM modulatory effects have also been
observed with experimental infection by Leishmania ama-
zonensis and Paracoccidioides brasiliensis both in vivo and in
vitro, where it has been shown to limit infection progres-
sion and dissemination [7,8]. CHM treatment in vivo
decreased IL-2 and IL-4 production, and cultures treated
with CHM exhibited differential expression of 147 genes
[9]. Moreover, CHM is neither toxic nor mutagenic [10].
Similarly, an improvement in the immune response of
treated mice has been demonstrated in studies with Sar-
coma 180. In these studies, there was a significant infiltra-
tion of lymphoid cells, granulation tissue and fibrosis
developed and surrounded the tumor, and sarcoma size
was reduced. All treated mice survived, and 30% exhibited
a total regression of the tumor. Treatment increased the
total numbers of leukocytes, specifically increasing B cells,
NK cells and CD4+ T cells [11]. These results suggest a
direct or indirect action of the medication on hematopoi-
esis. A subsequent microscopic study of bone marrow
cells showed that monocytic lineage (CD11b) and stro-
mal cells (adherent cells) were activated by treatment
[12,13].
Melanoma cells are highly malignant and have a pro-
found capacity to avoid detection by immune cells. Fur-
ther, the CHM evaluated here activates the immune
system by stimulating macrophages. Thus, we sought to
verify the communication between activated macro-
phages and lymphocytes by assessing cell-cell interactions
and anti-melanoma activity of lymphocytes co-cultured
with macrophages in the presence of the CHM.
Methods
Complex homeopathic medication – CHM
The CHM represents a new form of immunomodulatory
therapy and follows Hahnemann's ancient homeopathic
techniques. Mother tinctures were purchased from
authorized agencies sanctioned by the Brazilian Health
Ministry. These agencies assure the quality (endotoxin
free) and physico-chemical composition of their prod-
ucts. Starting from the original mother tincture – an eth-
anolic extract, in the case of a plant – several
dynamizations/succussion (shaking) and serial dilutions
in distilled water are performed. The CHM used to chal-
lenge macrophages is a complex matrix obtained from
Calcarea carbonica CH5 with associations, comprised of a
10%–20% concentration of each compound obtained
after vigorous shaking and five decimal dynamizations.
The final solution contains Aconitum napellus, Arsenicum
album, Asa foetida, Calcarea carbonica, Conium maculatum,
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Thuya occidentalis, all in decimal dilutions of Hahnemann
(dH) in distilled water. The resulting aqueous solution is
colorless and odorless, and has an alcohol concentration
< 1%. The medication was sterilized by filtration through
0.22 μm MILLEX GV Durapore PVDF membranes (Milli-
pore), maintained at room temperature and vigorously
shaken (succussed) immediately before each treatment.
Animals
Macrophages and lymphocytes were harvested from 2–3-
month-old male Swiss mice from the Central Animal
House of the Universidade Federal do Paraná (UFPR).
Experiments were performed at the Laboratório de
Pesquisa em Células Neoplásicas e Inflamatórias, UFPR,
which has a management program for produced residues.
All recommendations of the National Law (No. 6.638,
November, 5, 1979) for scientific management of animals
were observed, and the Institutional Animal Care Com-
mittee of UFPR approved all related practices. All experi-
ments were performed at least three times in triplicate,
and data analysis was performed in a double-blinded
manner.
Cell culture
Macrophages
Cells were harvested from the peritoneal cavity with cold
phosphate buffer saline (PBS), pH 7.4, and the number of
cells was determined using a Neubauer chamber. The cells
were plated in culture flasks and incubated at 37°C in a
humidified atmosphere containing 5% CO2. After incu-
bating for 15 min, non-adherent cells were removed by
washing. The remaining adherent cells, mainly macro-
phages, were cultured with Dulbecco's modified eagle's
medium (DMEM, GIBCO) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) containing 1 U/ml
penicillin, 1 μg/ml streptomycin, and 2.5 μg/ml ampho-
tericin (GIBCO), at 37°C in a humidified atmosphere
containing 5% CO2.
Lymphocytes
Lymph nodes were removed from the mesentery. The tis-
sue was dissociated using sterile Medicons (BD) and the
cell suspension was filtered with a 100-μm mesh filter
(Falcon, BD) to remove tissue fragments. After washing by
centrifugation, the final suspension was incubated in a
culture flask with PBS at 37°C in a humidified atmos-
phere containing 5% CO2. After incubating for 40 min,
non-adherent cells were transferred to sterile tubes,
washed three times with PBS and counted using an auto-
mated cell counter (CELM). These cells were plated and
cultured for each experiment.
Melanoma cells
Murine melanoma cells (B16F10), permanently main-
tained in the Department of Cellular Biology, Universi-
dade Federal do Paraná, were used for this study. Cells
were maintained in DMEM supplemented with 10% FBS
containing 1 U/ml penicillin, 1 μg/ml streptomycin, and
2.5 μg/ml amphotericin at 37°C in a humidified 5%CO2
atmosphere.
Experimental design
The following culture conditions were compared to sys-
tematically evaluate the action of the CHM:
B16F10 – melanoma cells only
B16F10/Ly – melanoma cells co-cultured with lym-
phocytes (Ly)
B16F10/Mϕ – melanoma cells co-cultured with macro-
phages (Mϕ)
B16F10/Ly-Mϕ – melanoma cells co-cultured with Ly that
were previously co-cultured with Mϕ
Mϕ/Ly – Mϕ co-cultured with Ly
Mϕ/Ly* – Mϕ co-cultured with Ly without cell contact
(0.4 μm insert)
Each culture condition was divided into two groups: (1)
CHM-treated, and (2) untreated (control). A 20% dose
was used based on a previously established standard treat-
ment protocol [5,6,9].
Co-culture assays
All co-culture assays were 48 h in duration, and were
repeated at least three times in triplicate. For Mϕ/Ly and
Mϕ/Ly* co-culture conditions, mesenteric lymph node
lymphocytes (5 × 106 cells/ml) and macrophages (106
cells/ml) were incubated for 24 h in the presence (treated)
or absence (control) of CHM. For the Mϕ/Ly* culture con-
dition, cells were cultivated in transwell plates (0.4-μm
pore size; Costar, Cambridge, MA), with macrophages in
the lower chamber and lymphocytes in the upper cham-
ber; both chambers shared the same medium and were
thus exposed to the same treatment.
Lymphocytes previously co-cultured with macrophages
for 24 h were isolated and incubated with 5 × 105 cells/ml
B16F10 cells (B16F10/Ly-Mϕ culture condition) in 24-
well culture plates and then cultured for 48 h, with or
without treatment.
Light microscopy
Cells grown under the culture conditions, B16F10,
B16F10/Ly, B16F10/Mϕ and B16F10/Ly-Mϕ, with or
without CHM treatment, were evaluated morphologically
to optimize culture procedures. The cells were plated onBMC Cancer 2009, 9:293 http://www.biomedcentral.com/1471-2407/9/293
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culture plates with cover slips [14,15], and maintained as
described above. After 48 h, cells were rinsed with PBS,
fixed in Bouin, stained with Giemsa, dehydrated and
mounted with Entellan. Adherent cells were observed by
light microscopy using a Nikon Eclipse E200 microscope.
Melanoma cell density was quantified in B16F10/Ly-Mϕ
culture condition by ImageJ software (NIH) selection and
pixel area quantification.
Scanning electron microscopy (SEM)
Culture conditions selected based on optical microscopic
screening of B16F10, Mϕ/Ly and B16F10/Ly-Mϕ (treated
or untreated), were observed by SEM. After culture, the
cells were fixed with 2.5% glutaraldehyde (0.1 M
cacodylate buffer, pH 7.2), washed and post-fixed in 1%
OsO4 for 30 min in the dark at room temperature [14,15].
After washing, the cells were dehydrated using increasing
ethanol concentrations. Cells were CO2  critical point
dehydrated, metallized and observed using a JEOL JSM-
6360 LV SEM at the Centro de Microscopia Eletrônica at
the UFPR.
Fluorescence microscopy
The apoptosis rate of melanoma cells was determined in
the B16F10/Ly-Mϕ culture condition (with and without
CHM treatment) selected based on observations from
optical and electron microscopy. DNA cleavage of adher-
ent lymphocytes and B16F10 cells was measured by
TUNEL (Terminal deoxynucleotidyltransferase dUTP
Nick-End Labeling) assay using the APO-DIRECT TdT-
mediated FITC-dUTP nick-end labeling kit as described by
the manufacturer (BD Pharmingen). After treatment,
adherent cells were fixed with 1% paraformaldehyde in
PBS (pH7.4) and then stored in 70% ethanol at -20°C
until stained. DNA strand breaks were labeled by incubat-
ing cells with 50 μl TUNEL reaction mixture containing
TdT and FITC-dUTP in binding buffer for 60 min at 37°C.
Cells were then washed and analyzed in an epifluores-
cence microscope DMLS2 (LEICA). Approximately 100
cells were counted for each cover slip, and a total of about
ten cover slips were observed and counted for each treat-
ment and time. Mean percentage data were transformed
as described in Statistical analysis.
Flow cytometry
For immunophenotypic analyses, an aliquot of lymph
node cells (106) was incubated with anti-CD3/FITC and
anti-CD4/PE, anti-CD8/PE, anti-CD19/PE or Pan-NK/PE
(BD Pharmingen) antibodies in PBS/1%FBS for 30 min,
and washed three times with PBS. Co-cultured lym-
phocytes from the culture conditions, Mϕ/Ly, Mϕ/Ly*
and B16F10/Ly-Mϕ (treated or untreated), were used to
determine CD25 expression and cell viability. These cells
(106) were incubated with anti-CD25/FITC (BD Pharmin-
gen) in PBS/1% FBS for 30 min, washed three times with
PBS and stained with 7-AAD (BD Pharmingen) for 10
min. For antibody specificity, see Table 1. The culture con-
dition Mϕ/Ly* was used to investigate the influence of
macrophages on lymphocytes activation in the absence of
cell contact. For each sample, 105 cells were acquired by
CellQuest software (BD) using a FACSCalibur (BD) flow
cytometer; the experiments were analyzed with WinMDI
2.9 software.
Statistical analysis
Percentage data obtained from apoptosis assays and flow
cytometry analyses were transformed to conform to a nor-
mal distribution using the equation, transformed data =
. Statistical significance of transformed data was
determined using a one-way analysis of variance
(ANOVA). Statistical significance is presented at the P <
0.05 (*) and P < 0.01 (**) levels. Data are representative
of three independent experiments.
Results
Altered melanoma cell morphology
An examination of cell cultures by light microscopy
showed no morphological differences between B16F10
cells treated with the CHM and untreated control cells (Fig
1A and 1B). Treated macrophages and lymphocytes exhib-
ited a greater degree of interaction than did control cells
(Fig 1C and 1D).
The melanoma cells from the culture conditions, B16F10/
Mϕ and B16F10/Ly, were smaller, indicating a discrete
response of the melanoma monolayer to macrophages
and lymphocytes (Fig 1E – 1H). This response appeared to
be somewhat increased in B16F10/Mϕ and B16F10/Ly
cultures treated with the CHM, but the difference was not
quantified.
The morphology of cells in the B16F10/Ly-Mϕ culture
condition was dramatically altered by the CHM treat-
ment. Lymphocytes previously in contact with macro-
phages and treated with the CHM were activated in some
manner such that they were capable of destroying B16F10
melanoma cells, resulting in a lower density monolayer of
x + 05 .
Table 1: Surface markers and viability stain. All antibodies and 7-
AAD used were purchase from BD Pharmingen.
Marker Main marked cells
CD3 T lymphocytes
CD4 Th lymphocytes
CD8 Tc lymphocytes
CD19 B lymphocytes
PanNK (DX5) NK lymphocytes
CD25 Activated lymphocytes
7-AAD Non-viable cellsBMC Cancer 2009, 9:293 http://www.biomedcentral.com/1471-2407/9/293
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Microphotographs of control and treated cultures Figure 1
Microphotographs of control and treated cultures. The cells were fixed, stained with Giemsa, and observed under a 
light microscope. Left column: control culture conditions; right column: treated culture conditions. (A and B) B16F10 cells; (C 
and D) Mϕ/Ly; (E and F) B16F10/Ly; (G and H) B16F10/Mϕ; (I and J) B16F10/Ly-Mϕ. Original magnification: 40× objective for all 
figures. Black arrow: B16F10 cells; thin black arrow: macrophages.BMC Cancer 2009, 9:293 http://www.biomedcentral.com/1471-2407/9/293
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melanoma cells (Fig 1I and 1J). Also the quantified
melanoma cell density was significant decreased after
treatment (Fig 2A–C).
Induction of cell clustering
An examination of cell cultures by SEM showed that
B16F10 melanoma cells grew as a monolayer of large and
spreading cells with many protrusions. This was true of
cells cultured with and without the CHM treatment (Fig
3A–B).
In Mϕ/Ly co-cultures, there was a clear physical interac-
tion between the two cell types (Fig 3C–D). These interac-
tions were enhanced by treatment with the CHM, which
resulted in clustering of lymphocytes on macrophages
(Fig 3D).
The B16F10/Ly-Mϕ culture condition selected from opti-
cal microscopy screening exhibited a decreased density of
melanoma cells, which failed to form a monolayer (Fig
3E–H). However, treatment of the same culture condition
with the CHM increased the reactivity of lymphocytes
towards melanoma cells, resulting in the destruction of
virtually all B16F10 cells (Fig 3F). Some cells in the CHM-
treated B16F10/Ly-Mϕ culture condition exhibited blebs
characteristic of apoptosis (Fig 3H).
Increased lymphocyte viability and expression of the acti-
vation marker, CD25, in CHM-treated Mϕ/Ly co-cultures
Flow cytometry was used to identify the proportion of
lymphocyte subsets in the mesenteric lymph node cell
population before co-culturing with macrophages. As
expected, the predominant cell population in murine
mesenteric lymph nodes was CD3+CD4+ (Table 2).
Micrographs of B16F10 cell density after B16F10/Ly-Mϕ culture condition of control and treated cells respectively (A and B) Figure 2
Micrographs of B16F10 cell density after B16F10/Ly-Mϕ culture condition of control and treated cells respec-
tively (A and B). Cell density was evaluated by cell area selection by ImageJ software and posterior pixel area quantification 
and comparison, showing a decrease of melanoma cell density on this culture condition (C). Original magnification: 40× objec-
tive for all figures.BMC Cancer 2009, 9:293 http://www.biomedcentral.com/1471-2407/9/293
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Scanning electron micrographs of control and treated cultures Figure 3
Scanning electron micrographs of control and treated cultures. Left column: control culture condition; right column: 
treated culture condition. (A and B) B16F10 cells after 48 h in culture; (C and D) Mϕ/Ly co-culture; (E and G) untreated 
B16F10/Ly-Mϕ; (F and H) CHM-treated B16F10/Ly-Mϕ. White arrow: B16F10 cell; thin white arrow; macrophages; Open-
headed arrow; lymphocytes.BMC Cancer 2009, 9:293 http://www.biomedcentral.com/1471-2407/9/293
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The expression of CD25, a marker of activated lym-
phocytes, was evaluated after co-culturing. In the Mϕ/Ly
culture condition, in which both cell types were in direct
contact with one another, CD25 expression and viability
were similar for lymphocytes with and without the CHM
treatment. After removing lymphocytes from co-cultures
and placing them with B16F10 cells (culture condition
B16F10/Ly-Mϕ), lymphocytes from the Mϕ/Ly* culture
condition, when cells was cultured in a Transwell system,
and could not contacted with one another, the treatment
allowed a significant increase in cell viability and CD25
expression when compared with respective control (Fig
4A and 4B; Table 3; Fig 5A). CD25 expression and viabil-
ity increased, as did the effectiveness of lymphocytes
against melanoma cells (Fig 4C–D; Table 3; Fig 5B).
Induction of apoptosis
Based on morphological evidence of apoptosis by elec-
tron microscopy, we selected the B16F10/Ly-Mϕ culture
condition for a more thorough analysis by TUNEL assay.
Using this technique, lymphocytes were distinguished
from melanoma cells by size and nuclear morphology. All
cell nuclei were stained red by propidium iodide and only
apoptotic cells were stained green by the TdT-mediated
FITC-dUTP nick-end labeling. Apoptosis was quantified
in both cell types, as well as in the lymphocyte clusters
attached to melanoma cells (Table 4), and the functional
activity of macrophage-co-cultured lymphocytes against
melanoma cells was analyzed by a one-way ANOVA. The
degree of cell-cluster formation (Fig 6) was significantly
higher with the CHM treatment (**P < 0.01), and the
number of apoptotic B16F10 cells was greater.
Discussion
Tumor cells use multiple mechanisms to escape detection
and elimination by the immune system, prompting the
development of chemotherapeutic drugs that harness
both humoral and cellular immunity to target malignant
cells. Innovative immunotherapy approaches include the
use of immunotoxins to eliminate regulatory T cells
(thereby allowing tumor-specific T cells to be activated),
monoclonal antibodies to inhibit immunosuppressive
cell signaling, and exvivo-expanded tumor-specific T cells
in combination with chemotherapy [16]. There is little
Table 2: Lymphocyte subpopulations in mesenteric lymph nodes. 
The mean percentage of each cell type determined by 
immunophenotyping assay is shown.
Markers %
CD3CD4 – Th lymphocytes 44.85
CD3CD8 – Tc lymphocytes 10.65
CD19 – B lymphocytes 9.86
PanNK – NK lymphocytes 3.95
Unstained cells 30.69
Table 3: CD25 expression in macrophage-stimulated 
lymphocytes in contact with B16F10 cells.
Mϕ/Ly
7-AAD viability
Mean Transformed mean P/F
Control 193 13.927 0.28
Treated 179 12.898
CD25 expression
Mean Transformed mean P/F
Control 1260.33 35.23 0.72
Treated 1150 33.788
Mϕ/Ly*
7-AAD viability
Mean Transformed mean P/F **
Control 1074.66 32.708 0.009
Treated 395.67 19.647
CD25 expression
Mean Transformed mean P/F **
Control 238.666 14.832 0.007
Treated 1119 33.323
B16F10/Ly-Mϕ
7-AAD viability
Mean Transformed mean P/F
Control 2368.7 48.3168 0.899
Treated 2985.583 54.0464
CD25 expression
Mean Transformed mean P/F *
Control 2295.8 59.6266 0.0113
Treated 3710.416 47.2793
Percentage data, obtained from light microscopy analysis, was transformed as 
described in Materials and Methods. Statistical significance of transformed 
data was determined by a single-factor ANOVA. Data are representative of 
three independent co-culture experiments.BMC Cancer 2009, 9:293 http://www.biomedcentral.com/1471-2407/9/293
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CD25 expression and viability of lymphocytes after co-culture Figure 4
CD25 expression and viability of lymphocytes after co-culture. (A and B) Lymphocytes co-cultured with macrophages 
for 24 h (treated or untreated) without cell contact (0.4 μm insert). In Ly/Mg* was observed a higher amount of unviable (7-
AAD+) Ly cells in control group (Fig. A). Unviable cells were not included in CD25 analysis for to keep comparison between 
viable CD25+ cells; (C and D) melanoma cells co-cultured with lymphocytes previously co-cultured with macrophages. Per-
centage of CD25 and viability (7-AADlow) subpopulations in lymphocytic cells are shown at the quadrant extremities.BMC Cancer 2009, 9:293 http://www.biomedcentral.com/1471-2407/9/293
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basic research on the effectiveness of homeopathic treat-
ments in cancer, and the few studies that have been per-
formed are limited in scope. One recent study examined
the anti-tumor effect of the homeopathic agent, Lym-
phomyosot, in a B16F10 invivo  model [17]. Previous
results in mice showed that CHM treatment significantly
reduced sarcoma size, infiltration of lymphoid cells, and
occurrence of granulation tissue and fibrosis surrounding
the tumor, and enhanced immune surveillance and pro-
moted tumor regression [10].
The CHM that we have used here is neither toxic nor
mutagenic. Our results show that it induces lymphocyte
activation against B16F10 cells, primarily under condi-
tions in which lymphocytes are stimulated by macro-
phages co-cultured (culture conditions Mϕ/Ly) in the
presence of the CHM. These lymphocytes were activated
by macrophage stimulation, even in the absence of cell
contact. Electron microscopy is a powerful tool for gain-
ing insight into the actions of homeopathic medicaments
in cancer [18], providing images that show the reduction
of melanoma cell density, membrane disruption, and
altered morphology of tumor cells. The cytotoxic effects of
macrophage-stimulated lymphocytes against B16F10 in a
liquid culture system were also evident in the form of
apoptotic cells detected by fluorescence and clearly seen
in SEM images (Fig 6 and Fig 3H) and by melanoma cell
density quantification (Fig 2). Although there was an
apparent increase in apoptotic melanoma cells after Mϕ/
Ly interaction, this difference was not significant, possibly
reflecting the ability of melanoma cells to suppress apop-
tosis by over-expressing anti-apoptotic factors [19]. Our
results showed that lymphocytes exerted a greater tumor-
icidal effect not only by inducing apoptosis but also by
causing cell lyses. This is consistent with the fact that lym-
phocytes can kill foreign or tumor cells by other cytotoxic
mechanisms, such as release of granzyme B or perforin
[20]. The B16F10/Mϕ culture condition did not show
increased effectiveness, probably because B16 melanoma
cells are capable of inhibiting macrophage activation [21].
Macrophages and dendritic cells both serve important
immunomodulatory functions, initiating a primary
immune response and also activating lymphocytes. Mac-
rophages can also regulate the intensity of the T-cell
response to a pathogen [22,23]. Tumor progression in
cancer may not simply result from the absence of an
immune response, but rather from the inability of effector
immune cells to control or destroy the tumor cells. The
interaction between antigen-presenting cells (APCs), like
dendritic cells and macrophages, and T cells is character-
ized by a bidirectional exchange of signals that can result
in activation and maturation of effector T lymphocytes
[24]. T lymphocytes have spontaneous anti-tumor activity
and are capable of killing tumor cells, but the anti-tumor
T cell can become inactive over time as a result of tumor-
escape mechanisms [25]. Activation of T cells is depend-
ent on APC-interaction mechanisms, and requires the
interaction of MHC complexes with TCR, co-stimulatory
molecules and/or mediators such as the cytokine, IL-2.
Expression of the IL-2 receptor α-chain (CD25) in acti-
vated lymphocytes confers greater effector capacity and
cellular proliferation [26,27]. Our results confirm this, as
evidenced by the fact that treatment with the CHM
increased lymphocyte expression of CD25 and lym-
phocyte viability in conjunction with enhanced effective-
ness against melanoma cells and showed to be important
to keep the lymphocyte viability in co-culture without
contact with macrophages.
Since this medication acts primarily through activation of
macrophages [4,9], it is possible that, after being acti-
vated, macrophages modulate lymphocyte activation
through membrane interactions or secretion of cytokines,
Lymphocyte CD25 expression and viability (7-AADlow) after  macrophage co-culture Figure 5
Lymphocyte CD25 expression and viability (7-AAD-
low) after macrophage co-culture. (A) Lymphocytes co-
cultured with macrophages for 24 h (treated or untreated) 
without cell contact (0.4 μm insert). CD25 expression and 
viability significantly increased after treatment. In Ly/Mg* was 
observed a higher amount of unviable (7-AAD+) Ly cells in 
control group. Unviable cells were not included in CD25 
analysis for to keep comparison between viable CD25+ cells. 
(B) Melanoma cells co-cultured with lymphocytes previously 
co-cultured with macrophages. Control lymphocyte CD25 
expression and viability significantly decreased after 24 h. Y-
axis: transformed mean.BMC Cancer 2009, 9:293 http://www.biomedcentral.com/1471-2407/9/293
Page 11 of 12
(page number not for citation purposes)
such as IL-2, and thereby improve antitumor activity
[28,29]. Other signaling pathways might also be involved
in this process. Lymphocyte clustering on B16F10 was sig-
nificantly increased in CHM-treated Mϕ/Ly co-cultures,
indicating that macrophage stimulation promoted the
interaction of lymphocytes with tumor cells. Many can-
cers and all melanomas express B7-H1 membrane pro-
teins, which inhibit lymphocyte responses by directly
inducing lymphocyte apoptosis. Pre-activated lym-
phocytes are better prepared to respond to this type of
cancer defense [30]. Tumor cells can manipulate the
immune microenvironment to their advantage, for exam-
ple, by promoting TNF-α secretion. TNF-α is rarely cyto-
toxic to tumor cells and promotes cancer growth, invasion
and metastasis, and controls the infiltration of antitumor
lymphocytes [31]. This CHM decreased TNF-α production
under pathological conditions, and exerted a positive
immunomodulatory function by activating macrophages
[4,9]. Individual lymphocytes appear not to be activated
by the treatment, indicating the importance of immune
cell interactions in general and macrophages in particular
in CHM-mediated lymphocyte activation.
Conclusion
In summary, the present study allows us to conclude that
this CHM indirectly activates lymphocytes through inter-
action with macrophages, even without direct cell-cell
contact. The co-culture of macrophages and lymphocytes
in the presence of the CHM promoted immunostimula-
tion of lymphocytes, resulting in enhanced tumoricidal
performance against a very aggressive lineage of
melanoma cells. In addition, the lymphocytes activated
by the treatment destroyed growing cancer cells more
effectively than did control lymphocytes. Finally, these
findings suggest that this medication is a promising com-
bination-therapy candidate, which may enhance the effi-
cacy of conventional medicines by improving the
immune response or even induce dormancy in tumor
cells.
Table 4: Quantification of TUNEL assay of B16F10/Ly-Mϕ culture 
conditions.
Apoptotic B16F10 cells
Mean Transformed mean P/F
Control 17 4.0945 0.0708
Treated 27.6666 5.1652
Apoptotic lymphocytes
Mean Transformed mean P/F
Control 24.75 4.6772 0.6539
Treated 22.11 4.9067
Cell cluster
Mean Transformed mean P/F **
Control 7.875 2.8636 0.00006
Treated 15.3333 3.9635
Percentage data, obtained from light microscopy analysis, were 
transformed as described in Materials and Methods. Statistical 
significance of transformed data was determined by a single-factor 
ANOVA. Data are representative of three independent experiments.
Apoptotic cells detected by TUNEL assay and analyzed by a one-way ANOVA Figure 6
Apoptotic cells detected by TUNEL assay and analyzed by a one-way ANOVA. Cell cluster formation was highly 
significant (P < 0.01), and apoptotic melanoma cell numbers were higher in treated cultures. Y-axis: transformed mean.BMC Cancer 2009, 9:293 http://www.biomedcentral.com/1471-2407/9/293
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